In a Chinese study, 26.3% (15/57) of patients diagnosed with LCNEC presented alterations in classical NSCLC driver genes, including missense mutations in KRAS, EGFR, and BRAF and amplifications in KRAS, EGFR, ERBB2, and MET, highlighting the potential of using targeted therapy. This evidence concerns the gene KRAS and large cell neuroendocrine carcinoma.